Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 5/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25023565 | 0.93 | RAB9A (0.44) | RAB9ANPC1MEN1ALDH1A1HPGD | |
| SCHEMBL30306801 | 0.87 | MEN1 (0.49) | RAB9ANPC1MEN1ALDH1A1HPGD | |
| SCHEMBL28968969 | 0.87 | MEN1 (0.49) | RAB9ANPC1MEN1ALDH1A1HPGD | |
| SCHEMBL25023561 | 0.87 | MEN1 (0.49) | RAB9ANPC1MEN1ALDH1A1HPGD | |
| SCHEMBL28969006 | 0.86 | RAB9A (0.43) | RAB9ANPC1 | |
| SCHEMBL25023560 | 0.83 | RAB9A (0.46) | RAB9ANPC1MEN1ALDH1A1HPGD | |
| SCHEMBL30306748 | 0.81 | TLR2 (0.43) | MEN1ALDH1A1HPGDKMT2ASIRT2 | |
| SCHEMBL24073357 | 0.78 | RAB9A (0.43) | RAB9ANPC1ALDH1A1KMT2AMAPT | |
| SCHEMBL25023564 | 0.76 | RAB9A (0.44) | RAB9ANPC1MAPTLMNATP53 | |
| SCHEMBL24073353 | 0.74 | RAB9A (0.46) | RAB9ANPC1ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156780-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-11951094-B2 | TLR2 modulator compounds, pharmaceutical compositions and uses thereof | AXIAL THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-4171547-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Axial Therapeutics, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TLR2, TLR3, TLR4 | RAB9A 4207/4885NPC1 1746/4885MEN1 4682/4885 |
| US-20240156780-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TLR2, TLR3, TLR4 | RAB9A 4207/4885NPC1 1746/4885MEN1 4682/4885 |
| US-11951094-B2 | TLR2 modulator compounds, pharmaceutical compositions and uses thereof | TLR2, TLR3, TLR4 | RAB9A 4207/4885NPC1 1746/4885MEN1 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.